Dr. Kornblum on Results of PrECOG 0102 in Breast Cancer

Noah S. Kornblum, MD
Published: Monday, Mar 06, 2017



Noah S. Kornblum, MD, assistant professor of medicine, Albert Einstein College of Medicine, attending physician of medicine, Montefiore-Einstein Center for Cancer Care, discusses the results from the PrECOG 0102 study, which explored the addition of everolimus (Afinitor) to fulvestrant (Faslodex) as a treatment for patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer.

The primary endpoint of the PrECOG 0102 study was progression-free survival (PFS). It was found that the combination of everolimus and fulvestrant doubled PFS from 5.1 months to 10.4 months. This has been consistent with the type of response seen in the BOLERO-2 trial looking at everolimus in combination with exemestane.

Fulvestrant alone had a PFS of 5.1 months, suggesting that in the aromatase inhibitor-resistant population, fulvestrant might be more beneficial to combine with everolimus, explains Kornblum.
 


Noah S. Kornblum, MD, assistant professor of medicine, Albert Einstein College of Medicine, attending physician of medicine, Montefiore-Einstein Center for Cancer Care, discusses the results from the PrECOG 0102 study, which explored the addition of everolimus (Afinitor) to fulvestrant (Faslodex) as a treatment for patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer.

The primary endpoint of the PrECOG 0102 study was progression-free survival (PFS). It was found that the combination of everolimus and fulvestrant doubled PFS from 5.1 months to 10.4 months. This has been consistent with the type of response seen in the BOLERO-2 trial looking at everolimus in combination with exemestane.

Fulvestrant alone had a PFS of 5.1 months, suggesting that in the aromatase inhibitor-resistant population, fulvestrant might be more beneficial to combine with everolimus, explains Kornblum.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x